IZOTROPIC CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.14 CAD | +16.67% |
|
+12.00% | +40.00% |
| 04-02 | Izotropic Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024 | CI |
| 01-30 | Izotropic Corporation Receives Response from U.S. FDA | CI |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 17.89M 24.45M 1.43B |
|---|---|---|---|---|---|
| Net income 2022 | -6M -8.2M -480M | Net income 2023 | -5M -6.83M -400M | EV / Sales 2022 | - |
| Net Debt 2022 | 172K 235K 13.74M | Net Debt 2023 | 1.97M 2.7M 158M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-4.47
x | P/E ratio 2023 |
-3.05
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 89.73% |
More Fundamentals
* Assessed data
More news
| 1 day | +16.67% | ||
| 1 week | +12.00% | ||
| Current month | +12.00% | ||
| 1 month | +16.67% | ||
| 3 months | +3.70% | ||
| 6 months | -28.21% | ||
| Current year | +40.00% |
1 week
0.11
0.14
1 month
0.110.15
Current year
0.100.22
1 year
0.100.40
3 years
0.101.27
5 years
0.101.56
10 years
0.101.56
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 71 | 18/05/16 | |
Ralph Proceviat
DFI | Director of Finance/CFO | 73 | 17/11/19 |
Younes Achkire
COO | Chief Operating Officer | - | 29/06/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ralph Proceviat
DFI | Director of Finance/CFO | 73 | 17/11/19 |
Alexander Tokman
BRD | Director/Board Member | 62 | 10/11/22 |
| Chief Executive Officer | 71 | 18/05/16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.14 | +21.74% | 6,500 |
| 25/04/24 | 0.115 | -14.81% | 4,500 |
| 24/04/24 | 0.135 | +17.39% | 61,461 |
| 23/04/24 | 0.115 | -8.00% | 24,050 |
Delayed Quote Canadian Securities Exchange, April 26, 2024 at 08:02 pm
More quotes
Izotropic Corporation is a Canada-based medical device company. The Company is commercializing IzoView, a computed tomography (CT) imaging system, which produces images of anatomy for non-invasive tissue characterization with the first application in breast imaging. The Company has not generated any revenue.
Calendar
22/08/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +40.00% | 5.62M | |
| -5.77% | 14.68B | |
| -40.71% | 2.71B | |
| -12.92% | 2.44B | |
| -8.78% | 1.51B | |
| -.--% | 1.12B | |
| +40.66% | 518M | |
| +91.79% | 502M | |
| +1.67% | 183M | |
| -.--% | 168M |
- Stock Market
- Equities
- IZO Stock
